Rituximab (anti-CD20)

Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1].

Product Specifications

CAS Number

[174722-31-7]

UNSPSC

12352203

Hazard Statement

H372

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rituximab-anti-cd20.html

Purity

99.10

Solubility

10 mM in H2O

Smiles

[Rituximab(anti-CD20)]

Molecular Weight

(143.47 kDa)

Precautions

P260-P264-P270-P501

References & Citations

[1]Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12 (2) :341-50.|[2]Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101 (3) :949-54.|[3]Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99 (3) :1038-43.